top of page

myLaminin Perspectives
Why Clinical Trial Start-Up Delays Still Happen and How CTMS Technology Is Fixing Them
Clinical trial start-up delays continue to impact site activation, budgets, and timelines due to fragmented workflows across feasibility, contracting, IRB/REB approvals, training, and system readiness. This article explains how CTMS platforms, integrated research systems, and AI-driven automation reduce inefficiencies by centralizing processes, improving visibility, and accelerating trial activation across global clinical research environments.

myLaminin
May 136 min read


ICH E6 (R3) Is Reshaping Clinical Trials. Here’s What Sponsors, CROs, and Research Sites Need to Know
Learn how ICH E6 (R3) is reshaping clinical trials through risk-based quality management, decentralized research oversight, data integrity, and continuous inspection readiness across global clinical research operations.

Deanne Bassili
May 115 min read


ICH E6 (R3) Is Here: What It Actually Means for Clinical Trials and Why It Matters Now
ICH E6 (R3) is reshaping clinical trial compliance across Canada, the U.S., EU, UK, and Australia. The updated Good Clinical Practice (GCP) guideline emphasizes Quality by Design, proactive risk management, audit trail traceability, sponsor oversight, informed consent, data integrity, and inspection readiness. myLaminin helps research teams and sponsors manage multi-site clinical trials with real-time oversight, CTQ monitoring, compliant eConsent, secure audit trails, and val

Deanne Bassili
May 74 min read


Multi-Site Clinical Trials: Hidden Operational Risks Impacting Trial Success
Multi-site clinical trials are widely used across North America to improve recruitment and accelerate timelines, but hidden operational risks often undermine success. Site variability, uneven engagement, communication breakdowns, and fragmented technology adoption create systemic inefficiencies that erode data quality and compliance. Without integrated oversight and standardized processes, complexity scales faster than control, increasing trial failure risk.

myLaminin
Apr 245 min read


The Real Cost of Poor Clinical Trial Coordination
Poor clinical trial coordination drives costly delays, data integrity risks, and regulatory exposure across multi-site studies in Canada, the US, and globally. Fragmented systems, inconsistent documentation, and weak communication slow approvals, inflate Phase III costs, and erode patient trust. Integrated CTMS/CR/os platforms like myLaminin unify stakeholders, streamline workflows, strengthen compliance, and enable real-time oversight turning coordination into a competitive

myLaminin
Apr 245 min read


bottom of page